We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Pathophysiology of hidradenitis suppurativa
- Hidradenitis suppurativa (HS/acne inversa)
- Current pathophysiological paradigm
- Paradigms: evolving concepts
- Observation: inflammation in HS
- Fibroblasts
- Complement in HS
- B cells in HS
- Future needs
- New insights
- Genetics of HS
- Gamma secretase polymorphisms
- Gamma secretase and notch signaling
- Epithelialized tunnels
- Tunnels in HS
- Inflammatory heterogeneity
- B cells/plasma cells in HS
- B cell-associated novel targets surrounding tunnels
- Antibody targets in HS
- Clinical features and diagnosis
- HS morphology
- The different HS morphologies
- Diagnostic criteria
- HS assessment and clinical grading (1)
- HS assessment and clinical grading (2)
- HS assessment and clinical grading (3)
- Outcome measures & comorbidity screening (1)
- Outcome measures & comorbidity screening (2)
- Comorbidity screening
- Treatment and lifestyle modifications
- Current therapeutics
- Guidelines in HS
- Non-pharmacological interventions
- Pain management
- Topical therapies
- Systemic antibiotics
- Other systemics
- Biologics
- Procedural interventions
- Treatment management pathway
- North American management guidelines
- Pipeline therapeutics
- Pathophysiology of HS
- TNF/IL-1
- Pipeline therapeutics
- Novel targets
- Other theoretical potential
- Thank you
Topics Covered
- Hidradenitis suppurativa (HS)
- Acne inversa
- Pathophysiology of hidradenitis suppurativa
- Treatment of hidradenitis suppurativa
- B cells in hidradenitis suppurativa
- Epithelialized tunnels
- Inflammation in HS
- HS Hurley staging
- HS outcome measures
- HS comorbidities
- Novel targets for HS
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Frew, J.W. (2023, January 31). Hidradenitis suppurativa: current understanding and management [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/WQJM2624.Export Citation (RIS)
Publication History
Financial Disclosures
- John W. Frew has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie, Azora, Novartis and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Azora and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche Posay.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Dr. John Frew.
I'm a dermatologist and
dermatological
researcher based at
the Department of Dermatology at
Liverpool Hospital in
Sydney, Australia.
I will be speaking to
you today regarding
hidradenitis suppurativa or HS,
including our current
understanding
of the pathophysiology,
clinical features, and
treatment of the disease.
0:23
These are some of my disclosures
regarding work in HS,
involvement in clinical trials
and involvement in
consulting work
for various pharmaceutical
and industry bodies.
0:37
First of all, today,
I will be speaking to
the pathophysiology of
hidradenitis suppurativa.
This is a complex and
ever-evolving area
of research and we understand
a great deal more about
the mechanisms involved in
HS than we did even a
few short years ago.
0:55
Clinically, hidradenitis
suppurativa,
also known as HS
or acne inversa,
is a chronic inflammatory
disease that manifests in
inflamed erythematous
nodules, painful,
malodorous draining tunnels,
as well as fluctuant
purulent abscesses
with a predilection
to flexural areas of skin.
It has an extremely
high disease burden
and impact on quality of life.
It affects individuals of
all backgrounds and ages,
but most commonly occurs in
late adolescence or in
individuals in their twenties.
Although there certainly is
some evidence to suggest that
middle aged individuals are
also prone to
developing the disease.
It is not an uncommon disease
and has an estimated prevalence
around 1 percent of
the general population in
all areas of the globe.